MedTrace Logo

Combination of AB-LIFE Probiotic Plus Monacolin K to Reduce Blood Cholesterol

NCT04677335 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-01-22

No results posted yet for this study

Summary

This randomized study evaluates the effectiveness of a nutraceutical combining billion colony forming units (cfu) of three L. plantarum strains (CECT7527, CECT7528 and CECT7529) and 10 mg of monacolin K in reducing blood cholesterol.

Conditions

Interventions

DIETARY_SUPPLEMENT

AB-LIFE with Monacolin K

Red yeast rice extract (also known by its scientific name, Monascus purpureus) certified to contain 10 mg of monacolin K, plus 1 billion total cfu of AB-LIFE probiotic formula, which is composed of 3 Lactoplantibacillus plantarum (formerly known as Lactobacillus plantarum) strains: CECT7527 (also known as KABP011™), CECT7528 (also known as KABP012™) and CECT7529 (also known as KABP013™), all in a maltodextrin carrier. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).

OTHER

Placebo

Placebo capsules containing maltodextrin carrier only. Capsules are of vegetable origin (hydroxypropylmethyl cellulose).

Sponsors & Collaborators

  • University of Extremadura

    collaborator OTHER

  • AB Biotics, SA

    lead INDUSTRY

Principal Investigators

  • Rafael Guerrero Bonmatty, PhD · University of Extremadura (SPAIN)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-01
Primary Completion
2016-04-15
Completion
2017-09-19

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04677335 on ClinicalTrials.gov